🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Supriya Lifescience Limited SUPRIYA NSEPHARMA

Healthcare · Biotechnology · India
https://www.supriyalifescience.com

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

READ MORE ›
₹968.70
+29.34% 1Y

Market & Price

Market Cap
₹7,796.37 Cr
Current Price
₹968.70
High / Low (52W)
₹968.70 / ₹553.35
Beta
0.45

Valuation

Stock P/E
37.32
Industry PE
37.60
Forward P/E
24.34
PEG Ratio
-
Book Value
₹134.51
Price to Book
7.20
P/S
10.60
EV/EBITDA
24.50
Dividend Yield
0.12%

Profitability & Returns

ROCE
22.38%
ROE
-
ROA
-
Profit Margin
25.19%
Op Margin
31.61%
EPS (Latest Qtr)
₹9.22
EPS (TTM)
₹25.96

Balance Sheet & Liquidity

Debt/Equity
0.48
Quick Ratio
-
Current Ratio
-
Debt
₹5.23 Cr
Total Assets
₹1,357.11 Cr
Current Assets
₹532.30 Cr
Working Capital
₹411.26 Cr

Ownership

Promoter Holding
70.84%
Chg in Prom Hold
-
FII / Inst Holding
4.66%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹6,401.23 Cr
Total Revenue (TTM)
₹735.46 Cr
EBITDA
₹261.24 Cr
Free Cash Flow
-
Operating Cash Flow
-
Shares Outstanding
₹8.05 Cr
Gross Margin
69.18%
Payout Ratio
3.85%

Growth (CAGR)

Revenue 5Y
22.44%
Profit 5Y
32.52%
Revenue (YoY)
11.20%
Earnings (YoY)
6.00%

PROS

  • Healthy ROCE of 22.4%.
  • Excellent profit margin of 25.2%.
  • Compounding revenue at 22.4% over 5 years.
  • Profit CAGR of 32.5% over 5 years.

CONS

  • In a downtrend (50-DMA below 200-DMA).
  • RSI at 87 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SUPRIYA Supriya Lifescience Limited NSEPHARMA 968.70 37.32 ₹7,796.37 Cr 0.12% 22.38% - 22.44% 32.52%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -185.65 Cr184.11 Cr145.07 Cr199.83 Cr206.44 Cr276.53 Cr
Cost of Revenue -61.78 Cr54.83 Cr31.77 Cr55.73 Cr61.20 Cr105.33 Cr
Gross Profit -123.87 Cr129.28 Cr113.30 Cr144.10 Cr145.24 Cr171.20 Cr
Operating Expenses -62.88 Cr67.78 Cr68.05 Cr78.09 Cr79.98 Cr82.08 Cr
Operating Income -60.99 Cr61.50 Cr45.25 Cr66.01 Cr65.26 Cr89.12 Cr
EBITDA -68.05 Cr70.56 Cr54.38 Cr75.37 Cr74.23 Cr101.09 Cr
Interest Expense -50.70 L41.70 L51.20 L41.50 L49.40 L46.80 L
Pretax Income -62.58 Cr64.06 Cr47.41 Cr68.32 Cr66.92 Cr92.13 Cr
Tax Provision -15.80 Cr13.68 Cr12.62 Cr17.89 Cr17.25 Cr17.90 Cr
Net Income -46.78 Cr50.38 Cr34.79 Cr50.43 Cr49.67 Cr74.23 Cr
Diluted EPS 5.715.826.294.326.276.179.22

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -451.01 Cr557.41 Cr696.49 Cr827.88 Cr
Cost of Revenue -230.55 Cr278.49 Cr211.18 Cr254.03 Cr
Gross Profit -220.46 Cr278.92 Cr485.31 Cr573.85 Cr
Operating Expenses -105.14 Cr121.17 Cr244.96 Cr308.21 Cr
Operating Income -115.32 Cr157.75 Cr240.35 Cr265.64 Cr
EBITDA -136.98 Cr185.20 Cr270.59 Cr305.08 Cr
Interest Expense -1.68 Cr3.70 Cr1.67 Cr1.89 Cr
Pretax Income -123.49 Cr165.69 Cr248.48 Cr274.78 Cr
Tax Provision -33.63 Cr46.58 Cr60.52 Cr65.66 Cr
Net Income -89.86 Cr119.11 Cr187.96 Cr209.12 Cr
Diluted EPS -11.1614.8023.3525.98

Compounded Sales Growth

5 Years:22.44%
1 Year:11.20%

Compounded Profit Growth

5 Years:32.52%
1 Year:6.00%

Stock Price Performance

1 Year:+29.34%
6 Months:+30.36%
3 Months:+44.72%
1 Month:+38.73%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -820.28 Cr921.45 Cr1,112.31 Cr1,357.11 Cr
Current Assets -464.89 Cr398.01 Cr437.04 Cr532.30 Cr
Cash & Equivalents -85.25 Cr68.35 Cr76.00 Cr37.55 Cr
Inventory -115.77 Cr85.25 Cr118.35 Cr159.60 Cr
Receivables -84.66 Cr111.68 Cr134.36 Cr219.45 Cr
Total Liabilities -120.82 Cr106.08 Cr115.55 Cr159.37 Cr
Current Liabilities -95.78 Cr77.11 Cr82.16 Cr121.04 Cr
Long Term Debt 0000-
Total Debt -22.47 Cr5.49 Cr5.38 Cr5.43 Cr
Total Equity -699.46 Cr815.37 Cr996.76 Cr1,197.73 Cr
Shares Outstanding -8.05 Cr8.05 Cr8.05 Cr8.05 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -63.60 Cr113.31 Cr164.68 Cr185.77 Cr
Investing Cash Flow --123.65 Cr-173.57 Cr-152.24 Cr-176.17 Cr
Financing Cash Flow --10.28 Cr-22.36 Cr-8.23 Cr-9.88 Cr
Capital Expenditure --107.91 Cr-145.66 Cr-162.38 Cr-152.24 Cr
Free Cash Flow --44.30 Cr-32.35 Cr2.30 Cr33.53 Cr
Net Change in Cash --70.33 Cr-82.63 Cr4.20 Cr-28.70 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -48.9%50.0%69.7%69.3%
Operating Margin % -25.6%28.3%34.5%32.1%
Net Margin % -19.9%21.4%27.0%25.3%
ROE % -12.8%14.6%18.9%17.5%
ROCE % -15.9%18.7%23.3%21.5%

Shareholding Pattern

Insiders
70.84%
Institutions
4.66%
Public Float
15.97%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SUPRIYA

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space